Placenta-specific 8 is a potential novel target for osimertinib resistance in non-small cell lung cancer

Currently, osimertinib (AZD9291) is the only third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor approved by the Food and Drug Administration for the treatment of non-small cell lung cancer (NSCLC) with EGFR T790M mutations. However, acquired resistance is an inevitabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Fei, Xiaoyun, Wang, Gang, Shen, Hui, Gu, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540393/
https://www.ncbi.nlm.nih.gov/pubmed/31289574
http://dx.doi.org/10.3892/ol.2019.10344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540393/
https://www.ncbi.nlm.nih.gov/pubmed/31289574
http://dx.doi.org/10.3892/ol.2019.10344

Ejemplares similares